Trump, Pence step in as heads of HHS, CMS clash

Amy Baxter | | Health Exec | Management

The relationship between CMS Administrator Seema Verma and HHS Secretary Alex Azar has become so fraught that both President Trump and Vice President Pence have stepped in to try to “salvage the situation,” which has threatened to undermine the administration’s healthcare agenda, Axios reported, citing three senior administration officials.

According to the report, Azar met with Verma in early December at the request of Pence. Previously, on Nov. 15, Trump “challenged Azar about his troubled working relationship with Verma,” and expects the two to work together for his healthcare agenda as the 2020 election creeps closer. Another November report by Politico laid bare just how sour the relationship between the two health leaders has turned over the past few years.

The collapse of the working relationship between Azar and Verma has already set back the administration’s agenda, including disrupting the rollout of initiatives such as Verma’s replacement for the Affordable Care Act.

See the full story below:

Scoop: Trump and Pence intervene in clash between top health officials

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.